These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34145182)

  • 1. Effects of Vortioxetine Versus Placebo on Cognition and Functional Capacity in Adults With Posttraumatic Stress Disorder.
    Durand D; Calcagno TM; Wong A; Newport DJ; Nemeroff CB; Dunlop BW; Harvey PD
    J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):501-503. PubMed ID: 34145182
    [No Abstract]   [Full Text] [Related]  

  • 2. Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder.
    Park C; Zuckerman H; Subramaniapillai M; Mansur RB; Rosenblat JD; Cao B; Iacobucci M; Lee Y; Levitan R; Blumberger DM; McIntyre RS
    Psychiatry Res; 2020 Feb; 284():112767. PubMed ID: 31978627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of vortioxetine in predator scent stress model of post-traumatic stress disorder in rats: role on neuroplasticity and apoptosis.
    Ozbeyli D; Aykac A; Alaca N; Hazar-Yavuz AN; Ozkan N; Sener G
    J Physiol Pharmacol; 2019 Aug; 70(4):. PubMed ID: 31642818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
    Levada OA; Troyan AS
    J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram.
    Sagud M; Nikolac Perkovic M; Dvojkovic A; Jaksic N; Vuksan-Cusa B; Zivkovic M; Kusevic Z; Mihaljevic-Peles A; Pivac N
    Psychopharmacology (Berl); 2021 Jun; 238(6):1575-1584. PubMed ID: 33560444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PHARMACOLOGY OF POST-TRAUMATIC STRESS DISORDER.
    Tregub T; Lytvynenko M; Kukushkin V; Chebotarova S; Oliynyk N; Gulbs O; Nazaryan R
    Georgian Med News; 2023 Sep; (342):122-124. PubMed ID: 37991966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls.
    Smith J; Browning M; Conen S; Smallman R; Buchbjerg J; Larsen KG; Olsen CK; Christensen SR; Dawson GR; Deakin JF; Hawkins P; Morris R; Goodwin G; Harmer CJ
    Mol Psychiatry; 2018 May; 23(5):1127-1133. PubMed ID: 28533517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study.
    Biederman J; Lindsten A; Sluth LB; Petersen ML; Ettrup A; Eriksen HF; Fava M
    J Psychopharmacol; 2019 Apr; 33(4):511-521. PubMed ID: 30843450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
    Iovieno N; Papakostas GI; Feeney A; Fava M; Mathew SJ; Iosifescu DI; Murrough JW; Macaluso M; Hock RS; Jha MK
    J Clin Psychiatry; 2021 Jun; 82(4):. PubMed ID: 34133089
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
    Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
    CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vortioxetine: A new alternative for the treatment of major depressive disorder.
    Salagre E; Grande I; Solé B; Sanchez-Moreno J; Vieta E
    Rev Psiquiatr Salud Ment (Engl Ed); 2018; 11(1):48-59. PubMed ID: 28800937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction.
    Keefe RSE; Nomikos G; Zhong W; Christensen MC; Jacobson W
    Int J Neuropsychopharmacol; 2018 May; 21(5):442-447. PubMed ID: 29546401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vortioxetine: A Review in Cognitive Dysfunction in Depression.
    Frampton JE
    Drugs; 2016 Nov; 76(17):1675-1682. PubMed ID: 27807822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials.
    Mahableshwarkar AR; Affinito J; Reines EH; Xu J; Nomikos G; Jacobsen PL
    CNS Spectr; 2020 Jun; 25(3):352-362. PubMed ID: 31199210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cognitive impairments in patients with depression].
    Schilling TM; Bossert M; Weisbrod M; Aschenbrenner S
    Nervenarzt; 2021 Mar; 92(3):277-288. PubMed ID: 33646323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder.
    Grant JE; Valle S; Cavic E; Redden SA; Chamberlain SR
    Int J Eat Disord; 2019 Jul; 52(7):786-794. PubMed ID: 30938842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC; Loft H; McIntyre RS
    J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid treatment of posttraumatic stress disorder with sibutramine.
    Annitto W; Mueller PS
    Epilepsy Behav; 2005 Nov; 7(3):565-6. PubMed ID: 16140592
    [No Abstract]   [Full Text] [Related]  

  • 19. Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine.
    Lachaine J; Beauchemin C; Bibeau J; Patenaude J; Chokka P; Proulx J; Bougie J
    CNS Spectr; 2020 Jun; 25(3):372-379. PubMed ID: 31120009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
    Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
    Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.